Aphios Awarded United States Patent for Antiviral Therapeutics
June 13, 2006
Woburn, MA — Aphios Corporation today announced that it has been awarded United States Patent No. 7,037, 534 B2 for chemiluminescence activated antiviral therapeutics.

The development of new antiviral agents is an important and difficult task. In general, compared to other classes of anti-infectives, there are far fewer drugs available in the field of antiviral therapy. The difficulties of developing antivirals result, in part, from viral replication taking place inside the infected cell while utilizing the cell's molecular machinery. Some viral diseases are virtually untreatable (hepatitis C, hemorrhagic fevers induced by flaviviruses Ebola, Lassa and related viruses). Moreover, a number of new and emerging viral agents (HIV, West Nile, hantavirus, influenza (H5N1)) have either entered or are threatening to enter the human population, some of which have caused or can cause serious epidemics and pandemics.

Currently, there are no drugs that are generally effective against different viral agents. Several compounds with broad antiviral activity have been reported, but none of them has attracted commercial development because of toxicity. There is, however, one class of compounds that do not produce substantial toxicity while at the same time having strong antiviral activity; compounds in this class all require light to exert their virucidal activity. Such compounds include the light-sensitive plant pigment hypericin isolated from St. John's Wort and many chemically related compounds.

The efficiency of hypericin-induced light-mediated viral inactivation is so high that even relatively short exposure times, which occur during routine tissue culture infection procedures, were sufficient for nearly complete inactivation of the exposed virus, notably HIV and other retroviruses. On the contrary, if a virus is treated with hypericin in complete darkness, then the virucidal effects are minimal, if at all detectable. Obviously, one should not expect any benefits from hypericin administration to patients afflicted by viral diseases since there's no light inside the organism. Despite this reasonable assumption, clinical studies of hypericin benefits for HIV and hepatitis C-infected individuals have been performed with the predictable negative result. These compounds do not work in the dark and thus, by themselves are not effective within the human body. We have circumvented this limitation by coupling light-sensitive compounds such as hypericin with chemiluminescence generated by native enzymes such as alkaline phosphatase present in normal tissues within the body. Additionally, we have enhanced antiviral efficacy by the addition of various anti-quenchers and wavelength-shifting compounds.

Aphios Corporation is a biopharmaceutical company that is developing enhanced therapeutics and biologics for health maintenance, disease prevention and the treatment of human diseases with a focus on infectious diseases, oncology and quality-of-life medicines.